Mashukur Rahman, Resident Doctor at Bangladesh Medical University, Medical Officer at Directorate General of Health Services, shared a post on LinkedIn:
“Top 15 Clinical Trials to Watch
Prostate Cancer
Precision and Treatment Intensification
- CIPHER
Platinum as a low-cost strategy in HRR-mutated mCRPC – expanding options beyond PARP inhibitors. - PSMAaddition
Lutetium-177 vipivotide tetraxetan moves earlier into mHSPC – radioligand therapy shifting to hormone-sensitive setting. - PEACE-2
Systemic intensification (abiraterone + ADT) combined with definitive prostate RT – optimizing local + systemic synergy. - PEACE-3
Radioligand + ARPI combination in mCRPC – targeting dual pathways in advanced disease. - CAPItello-281
AKT pathway inhibition in PTEN-deficient mHSPC – precision targeting of PI3K/AKT alterations.
Bladder and Urothelial Cancer
- ADC Revolution and Bladder Preservation
- KEYNOTE-B15 / EV-304
Perioperative enfortumab vedotin + pembrolizumab – potential new backbone in MIBC. - VOLGA
Triplet ADC-based perioperative strategy in MIBC – pushing intensification forward. - SunRISe-2
Bladder-sparing TAR-200 + cetrelimab in BCG-unresponsive NMIBC – redefining organ preservation.
Precision oncology. Radioligand expansion. ADC dominance.
ASCO GU 2026 is shaping the next phase of GU cancer care.”
Other articles featuring Mashukur Rahman on OncoDaily.